Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
Novello, Silvia;
2021-01-01
File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC_ The Results of TIGER-3, a Phase 3 Randomized Study _ Elsevier Enhanced Reader.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
6.18 MB
Formato
Adobe PDF
|
6.18 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.